Investigational drug · Phase 3
BMS-663068
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV Infections.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
17
Any phase or sponsor naming "BMS-663068"
First trial start
2015
Feb 23, 2015
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-663068", any sponsor or status.
- Phase 114
Conditions studied
As listed on its trial records.
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-663068" as an intervention, largest first.
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02362503 · 371 participants · Start Feb 23, 2015 · Primary completion Aug 18, 2016
Drug: BMS-663068 · For: HIV Infections
Sites: Los Angeles, California; Palm Springs, California; San Francisco, California · 139 sites in all
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT01384734 · 254 participants · Start Jul 26, 2011 · Primary completion Feb 18, 2013
Drug: BMS-663068 400 mg; BMS-663068 800 mg and 6 more · For: Infection, Human Immunodeficiency Virus
Sites: San Francisco, California; Washington D.C., District of Columbia; Coral Gables, Florida · 54 sites in all
ViiV HealthcareGSK (GSK)
NCT02480894 · 112 participants · Start Jul 7, 2015 · Primary completion Sep 21, 2015
Drug: BMS-663068; Maraviroc · For: Infection, Human Immunodeficiency Virus
Sites: San Antonio, Texas
- Drug-drug Interaction (DDI) RifabutinPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT02138084 · 102 participants · Start May 14, 2014 · Primary completion Jul 24, 2014
Drug: BMS-663068; Rifabutin and 1 more · For: Infection, Human Immunodeficiency Virus
Sites: Austin, Texas
ViiV HealthcareGSK (GSK)
NCT02666053 · 72 participants · Start Jan 27, 2016 · Primary completion Feb 22, 2016
Drug: BMS-663068 · For: Infection, Human Immunodeficiency Virus
Sites: Austin, Texas
ViiV HealthcareGSK (GSK)
NCT02467335 · 52 participants · Start Jan 29, 2015 · Primary completion Oct 3, 2015
Drug: BMS-663068 · For: Infection, Human Immunodeficiency Virus
Sites: Hamilton, New Jersey
- Study on PharmacokineticsCompleted
ViiV HealthcareGSK (GSK)
NCT02234882 · 50 participants · Start Sep 5, 2014 · Primary completion Oct 31, 2014
Drug: Rosuvastatin; BMS-663068 · For: HIV Infections
- Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1Completed
ViiV HealthcareGSK (GSK)
NCT01009814 · 50 participants · Start Nov 23, 2009 · Primary completion Jun 25, 2010
Drug: BMS-663068; Ritonavir · For: HIV Infections
Sites: Berlin, Germany
ViiV HealthcareGSK (GSK)
NCT02063360 · 42 participants · Start Feb 1, 2014 · Primary completion May 1, 2014
Drug: BMS-663068; Darunavir (DRV) and 2 more · For: Infection, Human Immunodeficiency Virus
ViiV HealthcareGSK (GSK)
NCT02164045 · 38 participants · Start Jun 24, 2014 · Primary completion Jul 25, 2014
Drug: BMS-663068 · For: Infection, Human Immunodeficiency Virus
Sites: San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV.
Benlarbi M, Richard J, Clemente T, et al. · J Infect Dis 2026
- Population pharmacokinetics and exposure-response relationship for temsavir following fostemsavir administration in treatment-experienced HIV patients.
Parasrampuria R, Thakkar N, Moore K, et al. · Pharmacol Res Perspect 2025
- Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage.
Boutin M, Medjahed H, Nayrac M, et al. · Viruses 2023
- Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.
Richard J, Prévost J, Bourassa C, et al. · Cell Chem Biol 2023
- Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.
Boutin M, Vézina D, Ding S, et al. · mBio 2022
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- JL18008Phase 21 trial
Jecho Biopharmaceuticals Co., Ltd. · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.